Trial Outcomes & Findings for Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC) (NCT NCT00672178)

NCT ID: NCT00672178

Last Updated: 2017-01-12

Results Overview

• Recruitment status: TERMINATED
• Study phase: PHASE1/PHASE2
• Target enrollment: 1 participants
• Primary outcome timeframe: 8 weeks
• Results posted on: 2017-01-12

Participant Flow

Recruitment: Jan 2008-Sept 2009. Study stopped early due to low accrual

Participant milestones

Measure	SBRT Stereotactic body radiotherapy concurrent with sorafenib
Overall Study STARTED	1
Overall Study COMPLETED	1
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)

Baseline characteristics by cohort

Measure	SBRT n=1 Participants Stereotactic body radiotherapy concurrent with sorafenib
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Age, Continuous	52 years n=5 Participants
Gender Female	1 Participants n=5 Participants
Gender Male	0 Participants n=5 Participants
Region of Enrollment United States	1 participants n=5 Participants

PRIMARY outcome

Timeframe: 8 weeks

Outcome measures

Outcome data not reported

Adverse Events

SBRT

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

John Kirkpatrick, MD, PhD

Duke University Medical Center

Phone: 919 668-7342

Email: kirkp001@mc.duke.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place